Bristol-Myers Squibb Compnay

Hoffmann-La Roche Inc.

Achal Mukundrao Pashine

Guodong Chen

Aaron Paul Yamniuk

Richard Yu-Cheng Huang

Stephen Michael Carl

Michael L Gosselin

Priyanka Apurva Madia

Derek A Holmes

Guy Georges

Stefan Seeber

Georg Fertig

Klaus Kaluza

Joerg Moelleken

Jens Fischer

Valeria Lifke

Scott Ronald Brodeur

Ekaterina G Deyanova

Sonja Offner

Lin Hui Su

Hong Shen

Yun Wang

Alfred Robert Langish

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Nucleic acids encoding anti-TREM-1 antibodies

Anti-TREM-1 antibodies and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Antibodies against IL-7R alpha subunit and uses thereof

Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

TL1A antibodies and methods of treatment

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc&#x3b3;Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R&#x3b1;). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

TL1A antibodies and uses thereof

An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

Antibodies against human IL33R and uses thereof

An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

Growing community of inventors

Mahwah, NJ, United States of America

Achal Mukundrao Pashine